Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Earlier, Apellis Wins FDA Approval For EMPAVELI To Treat Rare Kidney Diseases C3G And IC-MPGN With 68% Proteinuria Reduction

Author: Benzinga Newsdesk | July 29, 2025 03:32am

Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits
Broad label includes adults and adolescents with C3G or primary IC-MPGN, and post-transplant C3G disease recurrence
Well-established safety profile, consistent across >2,200 patient years in approved indications
C3G and primary IC-MPGN are rare kidney diseases with high risk of kidney failure

Posted In: APLS